期刊
ARTHRITIS CARE & RESEARCH
卷 66, 期 9, 页码 1374-1379出版社
WILEY
DOI: 10.1002/acr.22299
关键词
-
类别
资金
- Canadian Institutes of Health Research, Lupus UK
- Tolfo Family, Lupus Ontario
- Conn Smythe Foundation
- AbbVie
- BMS
- Eisai
- Eli Lilly
- Teva
- GSK
- MedImmune
- Pfizer
- Roche
- UCB
- Biostat
- Lilly
- Merck
- Vertex
- National Institute for Health Research [NF-SI-0512-10105] Funding Source: researchfish
Objective. The Medical Outcomes Study Short Form 36 (SF-36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the current study was to assess QOL over time in the first 5 years of a multicenter inception cohort of patients with SLE. Methods. An inception SLE cohort was assembled according to a standardized protocol between 2000 and 2012. In addition to clinical and laboratory assessments, patients completed the SF-36 at yearly intervals. Only patients who had >= 5 completed QOL questionnaires were included in these analyses. Generalized estimating equation models were run separately for each of the 8 subscales and for the physical and mental component summary scores, adjusting for repeated measures by patients. Results. A total of 495 patients were included. The mean +/- SD disease duration at the first visit was 5.3 +/- 4.1 months. The mean +/- SD age at enrollment was 35.8 +/- 13.2 years. All 8 subscales and the 2 summary scores showed improvement in the first 2 years from enrollment. Between years 2 and 5, none of the subscales or summary scores showed any change. Minimum clinically important improvement was achieved by 35-56% of the patients and was influenced by demographic and disease factors. Conclusion. Unlike late-stage lupus, where QOL is stable over time, in patients with early disease, all subscales improve in early followup up to 2 years. Therefore, the SF-36 may be a sensitive outcome measure in early disease in patients with SLE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据